Prestige Consumer Healthcare: Acquisitions Reshape the Growth Machine, Clear Eyes Remains the Long Game

For Prestige Consumer Healthcare, fiscal Q1 2027 was a turning point. Two acquisitions—the Breathe Right portfolio and LaCorium Health in Australia—closed within weeks of each other, instantly adding roughly $240 million in annualized revenue and a new category to the portfolio. Management raised full-year guidance, but the real story is how these deals, plus the ongoing Clear Eyes recovery, set up a multiyear transformation that blends scale with renewed brand-building firepower.

The Strategic Pivot: Breathe Right and LaCorium

The company wasted no time integrating. “As of this week, the business is largely integrated into our operations, running through our systems and our warehouse network with retailers ordering Breathe Right along with our existing brands.” — Ron Lombardi, Chairman, President and CEO · 2026-08-06 That’s less than 60 days after closing—a striking pace for a portfolio expected to generate roughly $200 million in annual sales. The launch of Breathe Right portfolio creates a new wellness, sleep, and other category, while LaCorium Health bolsters the International segment with the dermal Therapy brand.

The business is expected to generate approximately $200 million in annual revenue.

The rationale is familiar—brand building, synergies, and international expansion—but the execution is what stands out. LaCorium was a long-time watchlist item. As Ron Lombardi noted on the May call, “We've actually had this business on our radar screen for a very long period of time. It's actually in the same office building that our Care Pharma is outside of Sydney.” — Ron Lombardi, Chairman, President and CEO · 2026-05-14 Now it’s a new engine for the international algorithm.

Clear Eyes: Patience Is a Virtue

The Clear Eyes story remains a patient multiyear turnaround. The company now owns Pillar5, its sterile ophthalmic facility, but acknowledges volatility persists. “We're 2 quarters in, right? At the end of June, we had owned Pillar5 for just 2 quarters.” — Ron Lombardi, Chairman, President and CEO · 2026-08-06 Management reiterated that facility upgrades and management changes are underway, with expectations for improving output in the second half. But the Clear Eyes supply issues have kept the brand’s sales contribution below 3% of the company total, a far cry from its historical leadership position. The recovery plan is honest: consistent supply, rebuilt safety stock, full SKU availability, and then renewed marketing. That’s a multiyear road, but the category itself has shrunk, implying room to reclaim shelf space once supply stabilizes.

Financial Impact: Growth Comes at a Price

The deals boost reported revenue, but organic growth remains modest. Q1 revenue rose 6.5% as reported, yet only 3.2% organically excluding FX and acquisitions. Adjusted EPS grew 3% to $0.98, helped by record adjusted free cash flow of $83.7 million. But the financing is real: “Adjusted diluted EPS increased approximately 3% versus the prior year as the revenue increase was partially offset by higher interest expense from the acquisition.” — Christine Sacco, CFO and COO · 2026-08-06 The company now guides to a year-end leverage ratio just below 4x, with Effective Net Cash swinging from -$936 million to -$936 million in the latest quarter—almost unchanged on a sequential basis as the deals were financed with new term loans.

Management is confident it can pay down debt quickly, and legacy businesses like GI and skin care continue to offset order-timing noise. Yet the second quarter guidance anticipates a modest organic decline due to retailer order timing. The channel shift to e-commerce and value retailers remains a key theme, as consumers seek trusted brands at competitive prices. “And what we're seeing is more of a continuation of a channel shift. So we're picking up the consumption based on where they end up purchasing the product.” — Ron Lombardi, Chairman, President, and Chief Executive Officer · 2026-02-05

The Bottom Line

Prestige is betting that scale and brand diversity will accelerate organic growth once Clear Eyes recovers and acquisition synergies materialize. The upgraded guidance of $4.55–$4.65 EPS is reassuring, but the real payoff depends on execution—both in integrating Breathe Right and LaCorium and in bringing Clear Eyes back to full strength. For now, the market seems to be pricing in a cautious optimism, with the stock down 9% over the past 90 days as investors weigh the added debt against the long-term optionality.